



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 9/00, A61K 31/70 C07H 21/00, C12P 19/34		A1	(11) International Publication Number: <b>WO 93/15187</b> (43) International Publication Date: 5 August 1993 (05.08.93)		
(21) International Application Number: PCT/US93/00833 (22) International Filing Date: 28 January 1993 (28.01.93)		(74) Agent: GATES, Edward, R.; Wolf, Greenfield & Sacks, 600 Atlantic Avenue, Boston, MA 02210 (US).			
(30) Priority data: 07/829,729 31 January 1992 (31.01.92) US		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).			
(71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 28 Carleton Street, Cambridge, MA 02139 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(72) Inventors: USMAN, Nassim ; 3 Lawrence Street, Boston, MA 02116 (US). CEDERGREN, Robert, J. ; 4675 Christophe Colomb, Montreal, Quebec H2J 3G7 (CA). PERREAULT, Jean-Pierre ; 3291 Hanna Street, Rawden, Quebec J0K 1S0 (CA). YANG, Jing-Hua ; 2676 Monpetit Avenue, Montreal, Quebec H3T 1J6 (CA). RICH, Alexander ; 2 Walnut Avenue, Cambridge, MA 02116 (US).					
(54) Title: NUCLEOZYMES					
(57) Abstract					
Nucleozymes containing ribonucleotides and deoxyribonucleotides or nucleic acid analogues are described herein. The nucleozymes have catalytic activity and are significantly more resistant to degradation than their all-RNA ribozyme counterparts. Also described are methods for preparing the nucleozymes along with methods of using nucleozymes, e.g., as therapeutic agents.					

BEST AVAILABLE COPY

***FOR THE PURPOSES OF INFORMATION ONLY***

**Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.**

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

NUCLEOZYMESField of the Invention

This invention relates to nucleozymes, mixed nucleic acid polymers having catalytic activity. The invention also relates to methods of preparing and using nucleozymes.

Background of the Invention

Proteins were the only known catalysts of cellular reactions until the discovery of RNA catalysts (ribozymes). In some instances, the folded structure of a ribozyme catalyses a cleavage reaction on another part of the same molecule (cis-reaction). In other instances (trans-reaction), the ribozyme may also act as a catalyst on another RNA or DNA molecule (substrate) by cleaving or ligating pieces of the substrate without changing itself in the process.

(Zaug *et al.* Science, Vol. 231, pp. 470-75, 1986; Cech Science, Vol. 236, pp. 1532-39, 1987).

A well-characterized example of a ribozyme is the self-splicing Group I intron from the nuclear rRNA of Tetrahymena thermophila. An intron is an intervening sequence in a eukaryotic gene which does not encode a protein or in rare cases encodes a different protein. Introns are transcribed along with coding sequences (exons) to produce precursor RNA. The introns are removed from the precursor RNA and the exons are ligated by RNA cleaving and splicing steps. The Group I intron or ribozyme of T. thermophila catalyzes its own removal from the precursor RNA molecule. (Kruger *et al.* Cell

- 2 -

31:147-157, (1982); Zaugg et al. (1986)). The self-splicing ribozyme catalyzes a variety of phosphodiester transfer reactions. The ribozyme can act as a ribonuclease, ligase, phosphotransferase, acid phosphatase, polymerase and RNA restriction endonuclease (Zaugg, A.J., et al., Science 231:470-475 (1986); Zaugg, A.J., et al., Nature 324:429-433 (1986); Zaugg, A.J., et al., Biochemistry 25:4478-4482 (1986); Been, M.D., et al., Science 239:1412-1416 (1988); Doudna et al., Nature 339:519-522 (1989); all incorporated by reference herein).

The "hammerhead" and "hairpin" ribozymes also have been studied and described (Perreault et al., Nature 344:565-567 (1990); Perreault et al., Biochemistry 30:4020-25 (1991); Yang et al., Biochemistry 29:11156-60 (1990); Chowrira et al., Biochemistry 30:8518-22 (1991); Uhlenbeck Nature, 328:596-600 (1987)). The hammerhead ribozyme forms a stem loop secondary structure to form the catalytically active molecule. The hairpin ribozyme has a structure resembling a hairpin.

Although ribozymes are intriguing molecules, their use for in vivo applications is limited if not precluded. The all-RNA molecules are susceptible to degradation from enzymes (RNases) present in vivo. There presently is no way known to inventors for delivering such molecules to the intended site in an active form.

Summary of the Invention

The present invention is based on the discovery that ribozymes have catalytically critical sites and that it is not necessary to have an all-RNA molecule to have catalytic activity. The ribozyme like molecules of the invention or "nucleozymes" have ribonucleotides or nucleic acid analogues (hereinafter NAAs) at catalytically critical sites and NAAs or deoxyribonucleotides at non-catalytically critical sites. The preferred nucleozymes have ribonucleotides at catalytically critical sites. Nucleozymes have catalytic activity on the same substrates as their ribozyme counterparts.

The nucleozymes of the present invention thus essentially are modified ribozymes having at least a portion, or all, of the ribonucleotides replaced with deoxyribonucleotides or NAAs. The nucleozymes are significantly more resistant to degradation than their all-RNA ribozyme counterparts because the chemicals or enzymes present in vivo do not recognize the nucleic acid internucleotide bonds. The resistance can be to either enzymatic or chemical degradation. Preferably, a majority of the ribonucleotides of the ribozyme are replaced with deoxyribonucleotides or NAAs. The stability of the nucleozymes allows them to be useful as therapeutic agents whereas ribozymes would be cleaved and rendered inactive by enzymes, e.g. RNases, present in vivo.

- 4 -

The nucleozymes of the present invention are chimeric nucleic acid polymers having catalytic activity due to and preferably optimized by the presence of RNA or a NAA at a catalytically critical site. The present invention provides chemistry which allows synthesis of the chimeric polymers and the determination of catalytically critical sites. The sites may be determined by varying the location of deoxyribonucleotides in a chimeric polymer and determining the locations responsible for or related to the chimeric polymer's ability to catalyze.

The present invention also pertains to a method for making a chimeric polymer. The polymers are made by phosphitylating protected ribonucleotides or NAAs units under conditions to form substantially pure-protected phosphoramidites or synthons of a single isomer. The protected phosphoramidites are coupled to each other forming a protected chimeric nucleic acid chain. The protecting groups are removed from the chimeric nucleic acid chain under conditions which completely deprotect the polymer.

The method of the present invention alleviates problems associated with a known prior art method for preparing chimeric RNA/DNA polymers (Perreault et al. Nature 344:565-567 (1990); Wu et al. Journal of the American Chemical Society 111:8531-33 (1989)). The prior art synthetic method for making chimeric polymers had problems with the migration of the protecting groups during the phosphitylating step, difficulty in removing the protecting groups and also

has problems resulting from the process of removing the protecting groups in the deprotection step. The former problem results in the production of monomer units having protecting groups in an undesired position. The latter problem results, in many cases, in a) nucleotide modification, b) phosphodiester linkage isomerization, and c) to retention of a substantial amount of protecting groups on the polymer resulting in a non-functional polymer. The first problem was overcome in the present invention by selecting a catalyst capable of minimizing migration of protecting groups, e.g., a combination of 2,4,6-collidine and N-methylimidazole. The problem in removing the protecting groups was eliminated by deprotecting the mixed polymer in the presence of ethanolic ammonia.

The present invention also pertains to methods of using the nucleozymes. The nucleozymes may be used to perform the same catalytic functions as their all-RNA ribozyme counterparts. For example, a nucleozyme may be used as a ribonuclease, ligase, phosphotransferase, acid phosphatase, polymerase, or an RNA restriction endonuclease. The nucleozymes may be used to selectively cleave and ligate substrates by contacting the substrates with a nucleozyme such that the nucleozyme targets a specific sequence in the substrate for cleavage or ligation. The nucleozymes may be used as polymerases to polymerize the production of an oligoribonucleotide or an oligodeoxyribonucleotide. The nucleozymes also may be used in place of antisense RNA technology.

- 6 -

The nucleozymes also may be used as therapeutic agents introduced in vivo due to their resistance to chemical and enzymatic degradation. The nucleozymes may be used, for example, in a method for treating a subject for a retrovirus associated disease, e.g., human immunodeficiency virus (HIV). The method involves administering a therapeutically effective amount of at least one nucleozyme to the subject such that the nucleozyme cleaves the RNA genome of the retrovirus rendering it inactive. A plurality of nucleozymes also may be administered if it is desirable to target more than one sequence in the RNA genome.

A nucleozyme may be provided in a pharmaceutical composition. The pharmaceutical composition would include at least one nucleozyme and a pharmaceutically acceptable carrier.

It is an object of the present invention to provide a nucleozyme capable of maintaining its catalytic properties in vivo.

It is an object of the present invention to provide a chimeric nucleic acid polymer having catalytic activity.

It is yet another object of the present invention to provide a method for preparing chimeric polymers which are free of protecting groups and undesired isomeric side products.

It is yet another object of the present invention to provide a homogenous chimeric polymer.

- 7 -

Brief Description of the Drawings

FIG 1 depicts a structure of a hammerhead nucleozyme.

FIG 2 is a table listing nucleozymes of the present invention indicating the positions of ribonucleotides in the nucleozymes. The position designations correspond to the structure depicted in FIG 1.

FIGs 3 and 4 are photographs of a gel demonstrating the cleavage of a 5'-<sup>32</sup>P-labeled RNA substrate. The designation "RNA" is the all-RNA containing ribozyme and the nucleozymes are as abbreviated in FIG 2.

FIG 5 is a photograph of a gel demonstrating the cleavage of a radioactive RNA substrate by nucleozymes of the present invention containing methoxy substituted NAAs. The nucleozymes are abbreviated as in FIG 2.

FIGs 6 and 7 are graphs depicting the stability of nucleozymes compared to the stability of the all-RNA ribozyme counterpart after exposure to both RNase A (6) and a yeast cellular extract (7).

Detailed Description

The nucleozymes of the present invention have catalytic activity. Nucleozymes essentially are modified ribozymes preferably having at least one ribonucleotide or nucleic acid analogue (NAA) at a catalytically critical site(s) and deoxyribonucleotides or NAAs at non-critical sites.

The term "nucleozyme" is intended to include catalytic chimeric polymeric chains containing ribonucleotides and deoxyribonucleotides and/or nucleic acid analogues.

A ribozyme is an all-RNA containing molecule capable of being a biological catalyst. Ribozymes are at present recognized and examples of such molecules include the "hammerhead" or "hairpin" ribozymes.


The term "catalytic activity" is intended to include many types of catalysis. For example, the catalytic activity could be that of a ribonuclease, ligase, phosphotransferase acid, phosphatase, polymerase, and RNA restriction endonuclease.

The term "nucleic acid analogue" (NAA) is intended to include analogues which are structurally similar to ribonucleotides or deoxyribonucleotides and are capable of being monomer units in a polymer capable of hybridizing with DNA or RNA. The analogue may impart properties to a polymeric chain which differ from those of a nucleotide but the analogue is capable of being a monomer unit in a polymeric chain. The NAA may impart resistance to chemical or enzymatic degradation to the chimeric polymer. NAAs may be selected for their structural conformation if a particular conformation is desired for the polymer. A NAA which is structurally similar to a ribonucleotide may be positioned at a catalytically active site if the NAA is capable of participating and/or attaining the desired catalytic activity. Preferably, if the NAA is positioned at a


catalytically critical site it has a formula as depicted in Formulas I-IV below wherein X is a good coordinating ligand with divalent metal ions, e.g.,  $Mg^{+2}$ .

A nucleotide analogue may contain a heterocyclic ring as depicted in the formulae I-IV below or may be acyclic as shown in Formula V below. The preferred heterocyclic ring containing analogues of the present invention have three hydroxy substituents, alkoxy substituents or combinations thereof.


Formula (I)




Formula (III)




Formula (II)



Formula (V)



Formula (IV)



In the above formulae, B is a base. The base may be substituted or unsubstituted. Examples of bases include adenine, cytosine, guanine, uracil,

2-aminopurine, hypoxanthine, imidazole,  $R_1-C(=O)-O-$ ,

- 10 -

$R_1$ -SH-, and  $R_1$ -NH<sub>2</sub>- $^-$ . The term "base" is art-recognized and one of ordinary skill in the art would know which bases are useful in the present invention. X is selected from the group consisting of -OR<sub>1</sub>, F, -R<sub>2</sub>OH, -NH<sub>2</sub>, -R<sub>2</sub>NH<sub>2</sub>, -Br, -R<sub>2</sub>Br and -R<sub>2</sub>F wherein R<sub>1</sub> is a lower alkyl group and R<sub>2</sub>-R<sub>4</sub> are a lower alkyl hydrocarbon chains. The term "lower alkyl" is intended to include from one to six carbons, more preferably one to three carbons and most preferably a single carbon atom. For example, the most preferred X is methoxy.

B may be protected during the synthesis process. The protecting groups may be the conventional groups typically used in oligonucleotide synthesis processes e.g., N<sup>6</sup>-benzoyl for adenine, N<sup>4</sup>-benzoyl for cytosine, N<sup>2</sup>-isobutyryl for guanine, and N<sup>2</sup>-benzoyl for 2-aminopurine. Other useful protecting groups include phenoxyacetyl (PAC) and t-butoxyacetyl (TAC). One of ordinary skill in the art would know which protecting groups are appropriate for a particular base.

The NAAs capable of being positioned at a catalytically critical site may be determined by one of ordinary skill in the art using the following screening process. The catalytically critical sites of a particular ribozyme may be determined by positioning deoxyribonucleotides(s) at various locations within the ribozyme and evaluating the chimeric polymer's catalytic activity. After determining the locations of the catalytically

- 11 -


critical sites, NAAs may be substituted for the deoxyribonucleotide(s) and the chimeric polymer's catalytic activity is again evaluated. If the NAA containing chimeric polymer possesses catalytic activity then the NAA is suitable for positioning at a catalytically critical site.

The term "synthon" is intended to include the fully protected monomer units (phosphoramidites) used to assemble the nucleic acid analogues of a chimeric polymer chain. The term "nucleic acid analogue" is used to describe the units when polymerized as part of a chimeric polymer chain.

The term "chimeric polymer" is intended to include polymers containing at least two different types of monomer units, e.g., RNA, DNA, or NAA. For example, a chimeric polymer may include RNA/DNA, RNA/NAA, or DNA/NAA polymeric chains. It should be understood that the linkages between the building units of the polymeric chain may be linkages capable of bridging the units together for either in vitro or in vivo. For example, the linkage may be a phosphorous containing linkage, e.g., phosphodiester or phosphothioate, or may be a nitrogen containing linkage, e.g., amide. It should further be understood that the chimeric polymer may contain non-nucleotide spacer molecules along with its other nucleotide or analogue units. Examples of spacer molecules which may be used are described in Nielsen et al. Science, 254:1497-1500 (1991), the contents of which are expressly incorporated by reference.

- 12 -

The analogues described above may be prepared using synthetic methods capable of attaching the desired moieties at the selected positions. Other possible analogues will be apparent to one of ordinary skill in the art. Deoxyribonucleotides are readily available and may be purchased from a variety of sources. The alkyl substituted heterocyclic ring containing analogues may be synthesized by first reacting the moiety being modified with arabino triflates (trifluoromethane sulfonates) and second displacing the arabino triflates with an appropriate organotin compound selected on the basis of the desired moiety. A schematic of this reaction is depicted below:



This synthesis scheme may be used to prepare analogues wherein X is selected from the group consisting of  $-OR_1$ ,  $-R_2OH$ ,  $R_2F$ ,  $-RBr$ , and  $-RNH_2$ . One of ordinary skill in the art would know how to synthesize the halogenated analogues (X is  $-F$  or  $-Br$ ) and the amino substituted analogues (X is

-NH<sub>2</sub>). These analogues may be synthesized as described by Williams *et al.*, Biochemistry, 30:4001-4009 (1991), Doerr *et al.*, J. Org. Chem., 32:1462 (1967), Mengel *et al.* Angew. Chem., 90:557 (1978), or Coddington *et al.*, J. Org. Chem., 29:558 (1964), the contents of each of the references are hereby expressly incorporated by reference.

The acyclic nucleic acid analogues may be prepared by reacting a protected acyclic molecule with a diol. Reaction processes which may be used are described in Durand *et al.*, Nucleic Acid Research, 18:6353 (1990); Seela *et al.*, Nucleic Acid Research, 15:3113-3124 (1987); Cload *et al.*, JACF, 113:6324-6326 (1991), the contents of each reference is hereby expressly incorporated by reference.

The nucleozymes have catalytically critical site(s) at which a ribonucleotide or NAA is necessary for the nucleozyme to have the desired level of catalytic activity. The term "catalytically critical site" is intended to include sites which, if altered from a ribonucleotide or a NAA to a deoxyribonucleotide, substantially reduces or even eliminates catalytic activity. A substantial reduction in catalytic activity would be that reduction which limits the usefulness of the nucleozyme as a catalyst *in vitro* or *in vivo*. The catalytically critical sites may be determined for each nucleozyme. Catalytically critical sites can be determined by preparing a variety of chimeric polymers using the chemical techniques described

herein and comparing the catalytic activity of the chimeric test polymers. The catalytically critical sites in the all-RNA containing ribozyme counterparts are determined by selecting sites believed to be involved in catalysis and inserting a deoxyribonucleotide at the particular site. If the chimeric polymer does not have the same or substantially the same catalytic activity as the all-RNA counterpart, then the selected site is presumed to be a catalytically critical site. The hammerhead nucleozyme has four catalytically critical sites which are the G9, G12, A13 and A29 positions for the sequence depicted in FIG 1.

The nucleozymes of the present invention are of a size capable of being synthesized using the chemistry described herein. Preferably, the nucleozymes have less than about 100 total building units, more preferably, less than about 80 building units, even more preferably, less than about 70 building units, and most preferably less than about 50 building units. Some nucleozymes may even have less than about 20 building units. The preferred nucleozyme is modeled after the hammerhead ribozyme, the catalytic portion of which has 35 building units. The term "building unit" is intended to include ribonucleotides, deoxyribonucleotides, or synthons.

The nucleozymes of the present invention are modified ribozymes having at least a portion of the ribonucleotides replaced with deoxyribonucleotides or

- 15 -

NAAs. The modified ribozymes or nucleozymes are significantly more resistant to degradation than the all-RNA counterparts. The degradation may be either enzymatic or chemical degradation. The language "significantly more resistant to degradation" is that resistance which allows the nucleozyme to remain largely intact for an extended period of time relative to its all-RNA counterpart. Preferably it has a resistance which allows it to be administered for in vivo applications.

Resistance to enzymatic degradation may be resistance to enzymes present in vivo, e.g. RNases such as RNase A. FIGS. 6 and 4B are graphs depicting the relationship between the percentage of the nucleozyme being intact at a particular RNase A (FIG. 6) or yeast cellular extract (FIG. 7) concentration. The data set forth in FIGS. 6 and 7 was obtained using the following procedure. A sample of 0.001 pmol of 5' labeled nucleozyme or ribozyme was incubated with 0.5 mg of carrier tRNA in 50 mM Tris-HCl (pH 7.4) and 10 mM Mg<sup>+2</sup> and different concentrations of RNase A or yeast extract ten minutes for A, thirty minutes for extract. The reactions were stopped by the addition of 20 mM EDTA and loaded and analyzed on 15% PAGE in 7M urea. The yeast extract was prepared from a 1 ml culture of yeast strain BWG2-9A grown to late-lag phase, harvested and washed with 25 mM sodium phosphate buffer (pH 7.8). The pellet was suspended in 100  $\mu$ l of the same buffer and sonicated for 20 seconds

(60W). After centrifugation for five minutes in an Eppendorf centrifuge, the supernatant was used directly after appropriate dilutions and incubations with the nucleozymes and the all-RNA ribozyme.

As shown in FIG. 6, the nucleozymes were at least about 75% intact at an RNase A log concentration of -1.5 and at least about 80% intact at an RNase A log concentration of -2.5. Preferably, the nucleozyme is at least about 90% intact at both concentrations. The difference in stability between the nucleozymes and ribozyme is even more apparent when the enzyme is a yeast cellular extract (FIG. 7). The nucleozymes were at least 90% intact at all of the tested concentrations.

The chemical degradation for purposes of this invention is intended to include resistance to chemicals present in vivo and in vitro. The resistance may be to alkaline hydrolysis, e.g., sodium hydroxide and water.

The preferred nucleozymes of the present invention are modified ribozymes having a majority of the ribonucleotides replaced with deoxyribonucleotides or NAAs. At least one of the units is a deoxyribonucleotide and preferably most of the units are deoxyribonucleotides. The nucleozymes more preferably, have at least about 75%, even more preferably at least about 85%, most preferably at least about 90% of their ribonucleotides replaced with deoxyribonucleotides or NAAs. The nucleozyme also may be made up entirely of NAAs or a combination of NAAs and deoxyribonucleotides.

- 17 -

The present invention also pertains to a method of making a chimeric polymer. The method is similar to that described by Scaringe et al. to produce an all-RNA polymer. (Nucleic Acid Research Vol. 18, No. 18, 5433-41 (1990)), the contents of which is expressly incorporated by reference. The method includes the steps of phosphitylating protected RNA, DNA or NAA units under conditions which minimize migration of the protecting group forming isomerically pure protected phosphoramidites. The protected RNA or synthons may have the desired moieties protected with the protecting groups capable of surviving the phosphitylation and coupling steps. Examples of such groups include conventional DNA protecting groups such as 5'-O-DMT, N-Bz (Ade and Cyt), N-iBu (Gua),  $\beta$ -cyanoethyl for phosphate, TB DMS for 2'-hydroxyl.

The term "isomerically pure protected phosphoramidites" is intended to include phosphoramidite preparations free of a substantial amount of undesired isomers of the phosphoramidites. A substantial amount is that amount which would substantially interfere or impede with the preparation's ability to be used in forming a mixed polymeric chain. For example, a consideration in the chemical synthesis of a ribonucleotide phosphoramidite is contamination of the desired 2'-O-protecting group-3'-O phosphoramidite with the undesired 3'-O- protecting group -2'-O-phosphoramidite. Syntheses performed with the

latter lead to oligonucleotides having 5'-2' linkages. Isomerically pure protected phosphoramidites of the present invention lead to oligonucleotides which are free of such undesired linkages.

The method of the present invention also involves coupling the protected phosphoramidites together forming a protected chimeric polymeric chain. The coupling can be done using well-known chemical techniques known to one of ordinary skill in the art. Preferably the coupling is done on an automated synthesizer.

After the chimeric polymeric chain is formed, the protecting groups now can be removed from the chain under conditions which completely deprotect the polymer. Also, nucleotide base modification and/or phosphodiester linkage isomerization of the chain now can be minimized during the deprotection step.

The prevention of migration of the protecting groups in the phosphorylation step can be accomplished by phosphorylating in the presence of a catalyst selected to minimize migration. An example of such a catalyst is the combination of 2, 4, 6-collidine and N-methylimidazole.

The invention permits removal of the protecting groups in a manner that is complete and that minimizes nucleotide base modification and/or phosphodiester linkage isomerization. Complete removal of protecting groups includes substantially complete removal where a polymeric chain may have a

small number of protecting groups still attached which do not effect the polymeric chain's intended catalytic function. The deprotection step is accomplished by deprotecting the polymer in the presence of an agent capable of minimizing such effects. An example of such an agent is ethanolic ammonia.

The method also allows the production of a homogeneous RNA/DNA polymer free of undesired isomeric products. The term "free" is intended to include substantially free wherein a small amount of protecting groups or undesired isomers are present as long as the amount does not interfere or impede the polymer's function. The minimization of nucleotide base modification is intended to include that modification which would effect a polymeric chain's intended catalytic function. Minimizing phosphodiester linkage isomerization, when used in connection with a molecule, means preventing that degree of isomerization which would, adversely affect the molecule's intended catalytic function. Minimizing phosphodiester linkage isomerization when used in connection with a preparation, means preventing that degree of isomerization which would substantially affect the preparation's abilities to be used for its intended catalytic functions.

The present invention also pertains to methods for using the nucleozymes. The nucleozymes may be used for any method in which a ribozyme presently may be used. For example, the nucleozyme may be used to

selectively cleave an RNA substrate or to ligate two pieces of RNA together. When cleaving a substrate, the RNA substrate is contacted with at least one nucleozyme which targets a specific sequence in the substrate for cleavage. A plurality of nucleozymes also may be used in a cleavage process.

The nucleozymes of the present invention also may be used to polymerize an oligonucleotide molecule. The oligonucleotide may contain ribonucleotides, deoxyribonucleotides, and analogues of deoxy- or ribonucleotides. A template is contacted with a population of the appropriate nucleotide monomer units and a nucleozyme under conditions which allow an oligonucleotide complementary to the template to form. The template preferably is attached to a support.

The nucleozymes of the present invention also may be used for therapeutic methods due to their stability in vivo. The nucleozymes may be used, for example, to treat a subject for a retrovirus associated disease. A therapeutically effective amount of at least one nucleozyme is administered to a subject such that the nucleozyme(s) cleaves the RNA genome of the retrovirus or the viral mRNA rendering it inactive.

A retrovirus associated disease is intended to include diseases involving retroviruses. Retroviruses have an RNA genome making them susceptible to cleavage by the at least one nucleozyme or the plurality of nucleozymes. An example of such a retrovirus associated disease is AIDS wherein the causative retrovirus is the human immunodeficiency virus (HIV).

- 21 -

The term "subject" is intended to include living organisms susceptible to retroviruses, e.g., mammals. Examples of subjects include humans, cats, and rats.

The language "therapeutically effective amount" is intended to include that amount capable of eliminating or significantly reducing the symptoms associated with retrovirus associated diseases. The amount may be determined on an individual basis and will be based, at least in part, on consideration of the severity of symptoms to be treated, the results sought and the size of the subject. Thus, a therapeutically effective amount may be determined by one of ordinary skill in the art employing such factors using no more than routine experimentation.

The nucleozymes of the present invention also may be used in conjunction with or in place of antisense RNA technology. That is, to control the expression of a gene by targeting an appropriate mRNA. A nucleozyme may be selected based on its ability to target a particular mRNA sequence and subsequently an effective amount of the nucleozyme may be administered to a subject. The effective amount would be that amount necessary to target the RNA and control expression of a selected gene.

The present invention also pertains to pharmaceutical compositions containing at least one nucleozyme and a pharmaceutically acceptable carrier. The language pharmaceutically acceptable carrier is intended to include carriers capable of being co-administered with the nucleozyme(s) while not adversely affecting the nucleozyme(s) catalytic

activity. The carrier may be solid or liquid or a gel. Examples of liquid carriers include water, an aqueous solution of a non-toxic salt, e.g., sterile physiological saline solutions, or aqueous solutions containing organic solvents, e.g., ethanol. Also suitable are emulsions, such as oil-in-water. Solid carriers may include nutritive carriers, e.g., sucrose or gelatin, or non-nutritive carriers, e.g., cellulose or talc.

#### The Preferred Embodiment

The preferred nucleozymes of the present invention are modeled after the "hammerhead" ribozyme. The moderate size of the catalytic hammerhead domains of RNA lends itself to chemical synthesis. As shown in FIG. 1, the conserved hammerhead domain of around fifty ribonucleotides found in naturally occurring RNA has been petitioned between a thirty-five unit catalytic fragment 10, the ribozyme, and a fourteen nucleotide substrate unit 12.

The all-DNA analog of the hammerhead domain is inactive in catalysis. It was determined that nucleozymes containing as few as four ribonucleotides out of a total of thirty five nucleotides have catalytic activity. Active hammerhead nucleozymes require the presence of ribonucleotides in particular at four positions, particular the G9, G12, A13, and A29 positions shown in FIG. 2.

FIG. 2 is a table showing the chimeric polymers prepared along with the positions of ribonucleotides within the polymers. Nucleozymes are abbreviated as follows: DR and MR designate nucleozymes composed of

predominantly deoxyribonucleotides and 2'-methoxynucleotides, respectively. The following number indicates the number of ribonucleotides and the final number refers to a particular combination of ribonucleotides.

The all DNA analog of the hammerhead domain is inactive in catalysis. Several RNA/DNA mixed polymers appear as set forth and designated in the table of FIG 2. As shown in FIGS 3 and 4, the mixed polymer having ribonucleotides at positions 9, 10, 12, 13, 28, 29 and 30 of the ribozyme showed good catalytic activity (FIG 3). The nucleozyme containing the fewest ribonucleotides, DR4R3 and DR4R2, showed at least some activity. In FIGS 3 and 4, S indicates the mobility of the intact substrate and P, the product. RNA is the all-RNA ribozyme and nucleozymes are abbreviated as in FIG 1. The presence or absence of the enzymatic fragment is indicated by + or -, respectively in FIG 3. Lane 1 is a control lacking the added catalytic fragment in FIG 3. Lane 1 in FIG 4 is the 4.5 hour incubation of the substrate with neither  $Mg^{+2}$  nor nucleozyme and lane 2 is an incubation control in the presence of  $Mg^{+2}$  but no added nucleozyme. The samples were analyzed on 15% PAGE in 7M urea.

FIG 3 is a photograph showing the cleavage of radioactive substrates by OMe-nucleozymes. The S indicates the mobility of the intact substrate and P, the product. The reactions were performed as in FIG 2 except that the incubations of the substrate were with the MR5R nucleozyme, for four hours and the  $(Mg^{+2})$  was varied. Lane 1 contained no  $Mg^{+2}$ ,

- 24 -

lane 2-10 mM, lane 3-20 mM, lane 4-30 mM and lane 5-50 mM. The OMe-nucleozymes are nucleozymes having synthons which are methoxysubstituted in the 2' position. The nucleozymes designated MR contain all methoxysubstituted nucleozymes rather than deoxyribonucleotides.

The catalytic activity of the nucleozymes was further evaluated by determining parameters including  $K_M$  and  $K_{cat}$  for some of the kinetic reactions. In addition, the  $K_{Mg}$ ,  $K_s$  and  $k_3$  of nucleozyme reactions were obtained to evaluate how extensive deoxyribonucleotide substitution effects  $Mg^{+2}$  cofactor binding. A summary of these results is presented in Table 1 below.

TABLE I Kinetic parameters of nucleozyme-catalyzed reactions<sup>a</sup>


Substrate/ Nucleozyme	$K_M$ ( $\mu$ M)	$K_{cat}$ (1/min)	$K_s$ ( $\mu$ M)	$K_3$ (1/min)	$K_{Mg}$ (mM)
RS/DR4R3	4.2	0.004	5	0.013	23
RS/DR5R2	4.9	0.013	4	0.040	24
RS/DR7R	4.5	0.067	5	0.21	24
RS/RR	0.7	1.2	0.8	1.8	8.1

<sup>a</sup> The kinetic experiments were performed under the standard conditions of FIG 2 with following differences: the final concentrations were: nucleozyme 0.05  $\mu$ M; substrate from 0.5  $\mu$ M to 5  $\mu$ M;  $Mg^{+2}$  from 5 to 50 mM and the reaction times from 30 min to 6 h at 30°C. Initial rates were determined from the first 10% of the reactions. The chronology of substrate and metal ion addition is

- 25 -

currently not known. The values for  $K_s$ ,  $k_3$  and  $KMg$  were, therefore, determined from the following random assembly model for ternary complex formation:

The generalized reaction scheme used to determine the  $K$  values is depicted below.



The reaction scheme starts with the catalytic species, the substrate and the  $Mg^{2+}$  cofactor, traversing a ternary complex and yielding a product. The apparent  $K_m$ 's and  $K_s$ 's of the three nucleozymes are virtually identical and approximately five times those of the all-RNA ribozyme acting on an RNA substrate.

The chimeric polymers were synthesized as follows:

Ribonucleotide, Deoxyribonucleotide, or 2'-Methoxy Analogue Phosphoramidite Synthesis and Purification

Dry N-Acyl-5'-O-DMT-2'-O-sily-ribonucleoside (10 mmol, 1 eq) was dissolved in 30 ml dry THF in a 300 ml round bottom flask. 2, 4, 6-Collidine (75 mmol, 7.5 eq) was added followed by N-methylimidazole (5 mmol, 0.5 eq). (N,N-disopropylamino) (cyanoethyl) phosphonamidic chloride (20 mmol, 2.0 eq [22 mmol,

- 26 -

2.2 eq in the case of guanosine or other nucleotide bases with reactive lactams]) was then added dropwise over 5 min at room temperature. The reaction was clear at the start but a white precipitate formed within 3 min (this is the collidine hydrochloride salt). The reaction was complete after 1-2 hour (determined by TLC). The reaction was then placed in an ice bath and diluted with 100 ml (1 volume) ethyl acetate. 150 ml 5% NaHCO<sub>3</sub> was added slowly (the first 10 ml over 5 minutes). (In the case of guanosine the reaction was first quenched with 5 ml of absolute ethanol). Heat was generated by the quenching of excess phosphitylating reagent. The mixture was then transferred to a separatory funnel and a second volume of ethyl acetate (100 ml) was added after first rinsing out the reaction flask. The aqueous phase was removed and the organic phase washed with saturated NaCl. The combined aqueous washes were back extracted with 50 ml. ethyl acetate and the combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed in vacuo yielding a viscous oil. Coevaporation (x 5) with 50 ml toluene afforded the crude phosphoramidite as an offwhite foam or oil. Excess phosphinic acid and collidine caused it to be oily. After leaving the amidite under high vacuum overnight, resuspension and rotovaping of the amidite with methylene chloride and ethyl acetate usually produced a foam. The phosphoramidites were further purified by silica gel chromatography yielding a white foam in 75-85%

yields. This procedure was repeated for the preparation of the other desired phosphoramidites changing the initial protected nucleotide unit. The phosphoramidites were used to synthesize the mixed polymers using automated synthesis techniques commonly used for the synthesis of deoxyribonucleotides.

#### Automated Synthesis of Mixed Polymers

All syntheses were conducted on either a Gene Assembler Plus (Pharmacia), or a Cyclone (Milligen/Bioscience) synthesizer using standard protocols with an extended 12 min coupling step. A 30 fold excess (150  $\mu$ l of 0.1 M = 15 mg, ~ 15  $\mu$ mol) of the phosphoramidites and a 400 fold excess of tetrazole (400  $\mu$ l of 0.5M = 200  $\mu$ mol) relative to CPG bound 5'-hydroxyl was used in each coupling cycle. Synthesis scale was 0.5  $\mu$ mol. Average coupling yields on the Gene Assembler Plus, monitored by an on-line colorimeter, were ~99.0% and on the Cyclone 97-98%, determined by colorimetric quantitation of the trityl fractions. Reaction columns for 0.5  $\mu$ mol syntheses were Milligen/Bioscience 1.0  $\mu$ mol columns. Oligonucleotide synthesis reagents: 1) for GA plus: detritylation solution was 2% TCA in ethylene dichloride; capping was performed with 20% N-Methyl imidazoyl in THF and 10% acetic anhydride/10% 2,6-lutidine in THF; oxidation solution was 0.02  $M$   $I_2$ , 1% lutidine, 10% water in THF. Baker

Bio-Analyzed grade acetonitrile was further dried over activated 4 Å molecular sieves. Tetrazole solution (0.5 M in acetonitrile was obtained from Applied Biosystems. 2) for Cyclone: all standard DNA synthesis ancillary reagents were used.

#### Deprotection of Mixed Polymers

The CPG-bound mixed polymer was transferred from the synthesis column to a 4 ml glass screw top vial. 1 ml of ethanolic ammonia was added and heated at 55°C for 16 hr. After cooling to -20°C, the ethanolic ammonia was removed from the CPG beads and the CPG was washed with 0.5 ml of 50:50/ethanol:water which was then added to the ethanolic ammonia. The combined supernatants containing the oligoribonucleotide were dried to a white powder. To remove the silyl protecting groups, the ammonia-deprotected mixed polymer was resuspended in 50 µl of 50:50/ethanol:water and 600 µl of 1M TBAF/THF and left at room temperature for about 24 hr. The solution was then added directly to 10 ml of 0.1M TEAB and loaded onto a Qiagen 500 anion exchange cartridge (Qiagen Inc., Studio City, CA) prewashed with 10 µl of 0.05M TEAB, the nucleozyme was eluted with 7 ml of 2M TEAB and dried down to a white powder.

#### Gel Purification of Fully Deprotected Mixed Polymers

The oligomers were first checked by analytical PAGE (0.75 mm x 20 cm x 45 cm). 1 ODU of oligonucleotide in 5 µl H<sub>2</sub>O was added to 5 µl

of deionized formamide and the total 10  $\mu$ l solution was loaded into a 1 cm wide lane. Following electrophoresis the gels were photographed by placing the gel over a fluorescent TLC plate and illuminating the gel with a UV lamp. The desired sequence was established according to electrophoretic mobility and purified by preparative electrophoresis using 1.5 mm thick gels with a single 12 cm wide lane. After electrophoresis the desired band was excised, crushed, placed into a sterile 5 ml test tube, and covered with 50 mM  $\text{NH}_4\text{OAc}$  pH 7.0. The tube was covered and kept at 37°C O/N. The supernatant was then removed and the gel pieces washed with an additional 1 ml of the extraction buffer. The combined washings were filtered through a 0.45 micron filter and loaded onto a 1 gram size Sep-Pak C18 cartridge (Waters-Millipore) prewashed with 5 ml each of acetonitrile, 50% acetonitrile/0.1M TEAB and 0.1M TEAB. After washing the cartridge with 5 ml of 0.1 M TEAB, the RNA was eluted in 5 ml 35:35:30 acetonitrile/methanol/water and dried down to a white powder.

The mixed polymers set forth in the Table of FIG 2 were prepared as described above.

#### EQUIVALENTS

Those skilled in the art will be able to ascertain, using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein.

- 30 -

These and all other equivalents are intended to  
be encompassed by the following claims.

What is claimed is:

- 31 -

CLAIMS

1. A nucleozyme having catalytic activity, comprising:

a ribonucleotide and at least one second unit being a deoxyribonucleotide or nucleic acid analogue, the nucleozyme having a ribonucleotide or nucleic acid analogue at a catalytically critical site.

2. The nucleozyme as claimed in claim 1 including at least one deoxyribonucleotide.

3. The nucleozyme as claimed in claim 2 wherein all of the second units are deoxyribonucleotides.

4. A nucleozyme as claimed in claim 1 wherein the second units include at least one nucleic acid analogue.


5. A nucleozyme as claimed in claim 1 wherein the second units include at least 50% nucleic acid analogues.

6. A nucleozyme as claimed in claim 4 wherein the analogue contains a heterocyclic ring.

7. A nucleozyme as claimed in claim 4 wherein the analogue is acyclic.

- 32 -

8. A nucleozyme as claimed in claim 4 wherein the analogue has the following formula:




wherein B is a base and R<sub>3</sub> and R<sub>4</sub> are each independently lower alkyl groups.

9. A nucleozyme as claimed in claim 8 wherein B is selected from the group of adenine, cytosine, guanine, uracil, 2-aminopurine,


hypoxanthine, and imidazoyl, R<sub>1</sub>C=O-, R<sub>1</sub>-SH-, R<sub>1</sub>-NH<sub>2</sub>- wherein R<sub>1</sub> is a lower alkyl group.

10. A nucleozyme as claimed in claim 4 wherein the ribonucleotide analogue has a formula selected from the group consisting of:


Formula (I)




Formula (III)



Formula (II)



Formula (IV)



wherein B is a base and X is a good coordinating ligand for a divalent metal ion.

11. A nucleozyme as claimed in claim 10 wherein B is selected from the group consisting of adenine, cytosine, guanine, uracil, 2-aminopurine, hypoxanthine, and imidazoyl;

and X is selected from the group consisting of -OR<sub>1</sub>, F, -R<sub>2</sub>OH, and -CH<sub>2</sub>F, wherein R<sub>1</sub> is a lower alkyl group and R<sub>2</sub> is a lower alkyl chain.

12. A nucleozyme as claimed in claim 10 wherein the analogue has a formula as shown in (I) and X is methoxy.

13. A nucleozyme as claimed in claim 1 wherein the nucleozyme has a ribonucleotide at a plurality of catalytically critical sites.

14. A nucleozyme as claimed in claim 1 wherein the nucleozyme has less than about 100 total building units.

15. A nucleozyme as claimed in claim 14 wherein the nucleozyme has less than about 80 total building units.

16. A nucleozyme as claimed in claim 15 wherein the nucleozyme has less than about 70 total building units.

- 34 -

17. A nucleozyme as claimed in claim 16 wherein the nucleozyme has less than about 50 total building units.

18. A nucleozyme as claimed in claim 1 wherein the nucleozyme has a sequence corresponding to the ribozyme selected from the group consisting of hammerhead and hairpin.

19. A nucleozyme as claimed in claim 18 wherein the ribozyme is the hammerhead ribozyme.

20. A nucleozyme as claimed in claim 19 wherein the catalytically critical sites are the G9, G12, A13, and A29 positions.

21. A nucleozyme as claimed in claim 1 wherein the nucleozyme is selected from the group consisting of DR4R2, DR4R3, DR5R2, DR5R3, DR6R2, DR7R, MR5R2, MR3R, and MR2R.

22. A nucleozyme having catalytic activity, comprising:

a modified ribozyme having at least a portion of its ribonucleotides replaced with deoxyribonucleotides or nucleic acid analogs, the modified ribozyme being significantly more resistant to degradation than its all-RNA counterpart.

- 35 -

23. A nucleozyme as claimed in claim 22 wherein the resistance is to enzymatic degradation.

24. A nucleozyme as claimed in claim 22 wherein the resistance is to chemical degradation.

25. A nucleozyme as claimed in claim 22 or 23 wherein the modified ribozyme is a modified hammerhead ribozyme.

26. A nucleozyme as claimed in claim 22 wherein the resistance is to enzymatic degradation and the nucleozyme is at least 80% intact at an RNase A log concentration of -2.5.

27. A nucleozyme as claimed in claim 26 wherein the nucleozyme is at least 90% intact.

28. A nucleozyme as claimed in claim 22 wherein the resistance is to enzymatic degradation and the nucleozyme is at least 75% intact at an RNase A log concentration of -1.5.

29. A nucleozyme as claimed in claim 28 wherein the nucleozyme is at least 90% intact.

30. A nucleozyme as claimed in claim 25 wherein the resistance is to enzymatic degradation and the nucleozyme is at least 80% intact at an RNase A log concentration of -2.5.

- 36 -

31. A nucleozyme as claimed in claim 30 wherein the nucleozyme is at least 90% intact.

32. A nucleozyme as claimed in claim 25 wherein the resistance is to enzymatic degradation and the nucleozyme is at least 75% intact and an RNase A log concentration of -1.5.

33. A nucleozyme as claimed in claim 32 wherein the nucleozyme is at least 90% intact.

34. A nucleozyme having catalytic activity comprising

a chimeric polymer made up of RNA and second units being deoxyribonucleotides or nucleic acid analogues, said chimeric polymer having catalytic activity and having a majority of its total units being deoxyribonucleotides or nucleic acid analogs.

35. A nucleozyme as claimed in claim 34 wherein at least one of the second units is a deoxyribonucleotide.

36. A nucleozyme as claimed in claim 34 wherein all of the second units are deoxyribonucleotides.

37. A nucleozyme as claimed in claim 34 wherein the second units include a nucleic acid analogue.


- 37 -

38. A nucleozyme as claimed in claim 37 wherein the second units include a plurality of nucleic acid analogues.

39. A nucleozyme as claimed in claim 37 wherein at least one of the nucleic acid analogues contains a heterocyclic ring.

40. A nucleozyme as claimed in claim 37 wherein the nucleic acid analogue is acyclic.

41. A nucleozyme as claimed in claim 38 wherein the analogue has the following formula:




wherein B is a base and R<sub>3</sub> and R<sub>4</sub> are each independently lower alkyl groups.

42. A nucleozyme as claimed in claim 39 wherein the base is selected from the group of adenine, cytosine, guanine, uracil, 2-aminopurine,


hypoxanthine, and imidazoyl R<sub>1</sub>C=O-, R<sub>1</sub>-SH-, R<sub>1</sub>-NH<sub>2</sub>- wherein R<sub>1</sub> is a lower alkyl group.

43. A nucleozyme as claimed in claim 37 wherein the analogue has a formula selected from the group consisting of:


Formula (I)




Formula (III)



Formula (II)



Formula (IV)



wherein B is a base and X is a good coordinating ligand with a divalent metal ion.

44. A nucleozyme as claimed in claim 40 wherein the base is selected from the group consisting of adenine, cytosine, guanine, uracil, 2-aminopurine, hypoxanthine, and imidazoyl;

and X is selected from the group consisting of  $-OR_1$ ,  $F$ ,  $-R_2OH$ , and  $-CH_2F$ , wherein  $R_1$  is a lower alkyl group and  $R_2$  is a lower alkyl chain.

45. A nucleozyme as claimed in claim 43 wherein the analogue has a formula as shown in (I) and X is methoxy.

46. A nucleozyme as claimed in claim 34 wherein all of the second units are 2'-methoxy ribonucleotide analogues.

- 39 -

47. A nucleozyme as claimed in claim 34 wherein the nucleozyme is a modified hammerhead ribozyme.

48. A nucleozyme as claimed in claim 34 or 47 wherein at least 50% of the polymer is second units.

49. A nucleozyme as claimed in claim 48 wherein at least 75% of the polymer is second units.

50. A nucleozyme as claimed in claim 49 wherein at least 85% of the polymer is second units.

51. A nucleozyme as claimed in claim 50 wherein at least 90% of the polymer is second units.

52. A chimeric polymer including at least one ribonucleotide and at least one second unit being a deoxyribonucleotide or nucleic acid analogue, the polymer having catalytic activity optimized by the presence of RNA at a catalytically critical site.

53. A chimeric polymer as claimed in claim 52 wherein the second units include a deoxyribonucleotide.

54. A chimeric polymer as claimed in claim 52 wherein RNA is present at all of the catalytically critical sites.

- 40 -

55. A chimeric polymer as claimed in claim 53 wherein all of the second units are deoxyribonucleotides.

56. A method of making a chimeric polymer comprising:

phosphitylating protected RNA or second units under conditions to form substantially pure-protected phosphoramidites of a single isomer, the second units being deoxyribonucleotides or nucleic acid analogues;

coupling the protected phosphoramidites together forming a protected chimeric polymer chain; and

deprotecting the chimeric polymer chain under conditions which completely deprotect the chimeric polymer.

57. A method as claimed in claim 56 wherein the second units in the phosphitylating step include a deoxyribonucleotide.

58. The method as claimed in claim 56 or 57 wherein the phosphitylating agent in the phosphitylating step is (N,M-disopropyl amino) (cyanoethyl) phosphonamidic chloride.

59. A method as claimed in claim 56 or 57 wherein the phosphitylating step is conducted in the presence of 2,4,6-collidine and N-methylimidazole.

- 41 -

60. A method as claimed in claim 58 wherein the phosphitylating step is conducted in the presence of 2,4,6-collidine and N-methylimidazole.

61. A method as claimed in claim 56 wherein the deprotecting step is conducted in the presence of ethanolic ammonia.

62. A method as claimed in claim 59 wherein the deprotecting step is conducted in the presence of ethanolic ammonia.

63. A chimeric polymer containing ribonucleotide units and second units joined together forming a chimeric polymer, the second units being at least one deoxyribonucleotide or nucleic acid analogue and the chimeric polymer being free of protecting groups.

64. A chimeric polymer as claimed in claim 63 wherein the second units include deoxyribonucleotides.

65. A homogeneous RNA/DNA polymer containing both deoxyribonucleotide and ribonucleotide units joined together forming a mixed polymer, the mixed polymer being free of undesired isomeric products.

66. A homogeneous polymer as claimed in claim 65 wherein the undesired isomeric products contain 5-2 linkages.

- 42 -

67. In a chimeric nucleotide polymer synthesis, the improvement comprising, the use of a catalyst capable of minimizing migration of protecting groups during a phosphorylation step.

68. A method as claimed in claim 67 wherein the catalyst is a combination of 2,4,6-collidine and N-methylimidazole.

69. In a chimeric nucleotide polymer synthesis, the improvement comprising, the removal of protecting groups from a protected mixed polymer in the presence of ethanolic ammonia.

70. A method for selectively cleaving an RNA substrate, comprising:

contacting a substrate with a nucleozyme which targets a specific sequence in the substrate for cleavage.

71. A method for treating a subject for a retrovirus associated disease, comprising:

administering a therapeutically effective amount of a nucleozyme to the subject such that the nucleozyme cleaves the RNA genome of the retrovirus or viral m RNA rendering it inactive.

72. A method as claimed in claim 71 wherein a plurality of nucleozymes are administered.

- 43 -

73. A method as claimed in claim 71 wherein the retrovirus is human immunodeficiency virus.

74. A pharmaceutical composition, comprising:  
at least one nucleozyme; and  
a pharmaceutically acceptable carrier.

75. A method of polymerizing an oligonucleotide molecule comprising:

contacting a template with a population of nucleotide monomer units and a nucleozyme such that an oligonucleotide complementary to the template is formed.

76. A method as claimed in claim 75 wherein the oligonucleotide formed is an oligoribonucleotide.

77. A method as claimed in claim 75 wherein the oligonucleotide formed is an oligodeoxyribonucleotide.

78. A method as claimed in claim 70 wherein the RNA is messenger RNA.

79. A method for controlling the expression of a gene in a subject comprising:

selecting a nucleozyme which targets an RNA sequence involved in the expression of a gene;  
administering an effective amount of the selected nucleozyme to the subject such that the nucleozyme targets the RNA sequence and inhibits the expression of a gene.




FIG 1

	Position of ribonucleotide		
	$rG^9rA^{10}$	$rGrA^{12,13}$	$rArArG^{28,29,30}$
<b>Nucleozyme</b>			
DR2R	rG	rA	--
DR3R	rG	rA	rA
DR4R1	rG	rA	rArG
DR4R2	rG	rGrA	rG
DR4R3	rG	rGrA	rA
DR5R2	rG	rGrA	rArG
DR5R3	rGrA	rGrA	rG
DR6R2	rGrA	rGrA	rArG
DR7R	rGrA	rGrA	rArArG
<b>OMe-nucleozyme</b>			
MR2R	rG	rA	--
MR3R	rG	rA	rA
MR5R	rG	rGrA	rArG

FIG 2

FIG 3




FIG 4





FIG 5



5 / 6

FIG 6





FIG 7



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/00833

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C12N9/00; A61K31/70; C07H21/00;		C12P19/34
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	C12N ; A61K ; C07H	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	WO,A,9 103 162 (CITY OF HOPE) 21 March 1991 see the whole document	1-3, 13-20 22-23, 25-36, 47-57, 63-66, 70-71 73-74, 78-79 56-62, 67-69
Y	----- -----	-/-
<p><sup>10</sup> Special categories of cited documents :<sup>10</sup></p> <p><sup>"A"</sup> document defining the general state of the art which is not considered to be of particular relevance</p> <p><sup>"E"</sup> earlier document but published on or after the international filing date</p> <p><sup>"L"</sup> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p><sup>"O"</sup> document referring to an oral disclosure, use, exhibition or other means</p> <p><sup>"P"</sup> document published prior to the international filing date but later than the priority date claimed</p> <p><sup>"T"</sup> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p><sup>"X"</sup> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p><sup>"Y"</sup> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p><sup>"S"</sup> document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
3 Date of the Actual Completion of the International Search 27 MAY 1993		Date of Mailing of this International Search Report 03.06.93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer ANDRES S.M.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category <sup>a</sup>	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claims No.
X	NUCLEIC ACIDS RESEARCH vol. 18, no. 18, 25 September 1990, ARLINGTON, VIRGINIA US pages 5433 - 5441 SCARINGE, S.A. ET AL. 'Chemical synthesis of biologically active oligoribonucleotides using beta-cyanoethyl protected ribonucleoside phosphoramidites' cited in the application see the whole document	56-62
Y	---	56-62, 67-69
X	SCIENCE vol. 253, 19 July 1991, LANCASTER, PA US pages 314 - 317 PIEKEN, W.A. ET AL. 'Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes' see the whole document	1,4-6, 10-11, 13-20, 22-23, 25-34, 37-39 42-43, 47-48, 52,54, 56,63,70
X	---	1-3, 13-20, 34-35, 47, 52-54, 63-66,70
X	BIOCHEMISTRY vol. 30, no. 16, 1991, EASTON, PA US pages 4020 - 4025 PERREAU, J.-P. ET AL. 'Relationship between 2'-hydroxyls and magnesium binding in the hammerhead RNA domain: a model for ribozyme catalysis' cited in the application see the whole document	75-76
X	WO,A,8 804 300 (UNIVERSITY PATENTS, INC.) 16 June 1988 see page 16, line 10 - page 17, line 24; claim 72	75-76
X	---	75-76
X	SCIENCE vol. 251, 20 March 1991, LANCASTER, PA US pages 1605 - 1608 DOUDNA, J.A. ET AL. 'A multisubunit ribozyme that is a catalyst of and template for complementary strand RNA synthesis' see the whole document	-/--

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	<p>BIOCHEMISTRY vol. 31, no. 21, 2 June 1992, EASTON, PA US pages 5005 - 5009 YANG, J.-H. ET AL. 'Minimum ribonucleotide requirement for catalysis by the RNA hammerhead domain' see the whole document</p> <p>---</p>	1,4-6, 10-34, 37-39, 42-52, 54,56, 58-63 67-70
P,X	<p>EMBO JOURNAL vol. 11, no. 5, May 1992, EYNSHAM, OXFORD GB pages 1913 - 1919 PAOLELLA, G. ET AL. 'Nuclease resistant ribozymes with high catalytic activity' see the whole document</p> <p>---</p>	1,4-6, 10-20, 22-34, 37-39, 42-43, 45-52,63 70
P,X	<p>WO,A,9 207 065 (MAX-PLANCK GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.) 30 April 1992 see page 4, line 6 - page 7, line 3 see claims; example 4</p> <p>-----</p>	1,4-6, 10-11 13-20 22-34, 37-39, 42-44 47-52, 54,63, 70-71, 73-79

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/00833

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 71-73 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

## Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

US 9300833  
SA 70071

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 27/05/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9103162	21-03-91	AU-A-	5817790	08-04-91
		DE-T-	4091533	30-01-92
		EP-A-	0451221	16-10-91
		EP-A-	0506666	07-10-92
		GB-A-	2242432	02-10-91
		JP-T-	4502256	23-04-92
		WO-A-	9206988	30-04-92
		US-A-	5149796	22-09-92
WO-A-8804300	16-06-88	US-A-	4987071	22-01-91
		EP-A-	0291533	23-11-88
		JP-T-	1501445	25-05-89
		US-A-	5037746	06-08-91
		US-A-	5116742	26-05-92
		US-A-	5093246	03-03-92
WO-A-9207065	30-04-92	None		

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**